{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T08:03:30Z","timestamp":1784621010719,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Previous research has shown that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have cardioprotective effects. However, their efficacy in acute myocardial infarction (AMI) is not yet well established. We conducted a systematic review and meta-analyses to assess the impact of GLP-1 RAs in AMI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched major databases for studies in patients with ST-elevation (STEMI) or non-ST-elevation myocardial infarction (NSTEMI). These included MEDLINE (accessed via PubMed), Excerpta Medica dataBASE (Embase), Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov, and Google Scholar from their inception through February 2026. PRISMA guidelines were used to conduct this review. Both randomized controlled trials (RCTs) and observational studies were included in the systematic review. However, only RCTs were included in the meta-analyses. The primary outcome was infarct size relative to the area at risk (AAR). Secondary outcomes included major adverse cardiovascular events (MACE) and safety outcomes (nausea, hypoglycemia, pancreatitis). The Cochrane Risk of Bias 2 (RoB 2) tool and Newcastle-Ottawa Scale (NOS) were used to assess risk of bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included eight studies with a total of 1,483 participants. GLP-1 RAs led to a smaller infarct size indexed to the AAR compared with placebo. The mean reduction was 10.14% points (95% confidence interval [CI]: \u221214.11\u2013\u22126.17;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). The primary infarct-size analysis was based on only three RCTs. GLP-1 RAs led to an improvement in the left ventricular ejection fraction (LVEF). The absolute mean improvement was 2.93% points (95% CI: 0.18\u20135.67;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). Subgroup analyses were conducted to explore the findings in greater detail. They revealed that liraglutide was associated with an even higher absolute increase in LVEF. The absolute mean improvement was 5.32% points (95% CI: 3.49\u20137.15;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01). Nausea was more frequent in the treatment group, while hypoglycemia and pancreatitis were not significantly increased. Limitations included relatively small sample sizes in the individual studies, short follow-up periods, and variability in study designs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with AMI, GLP-1 RAs reduce relative infarct size and improve LVEF. No clear safety signal was detected in the available short-term trial data, except for increased nausea. These results indicate that GLP-1 RAs could be beneficial as an additional treatment in AMI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s43044-026-00767-y","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:21:16Z","timestamp":1784618476000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A systematic review and meta-analyses of glucagon-like peptide-1 receptor agonists in acute myocardial infarction"],"prefix":"10.1186","volume":"78","author":[{"given":"Jasmin Kaur","family":"Bhullar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol","family":"Bahekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"2","key":"767_CR1","doi-asserted-by":"publisher","first-page":"e1004343","DOI":"10.1371\/journal.pmed.1004343","volume":"21","author":"M Hall","year":"2024","unstructured":"Hall M, Smith L, Wu J, Hayward C, Batty JA, Lambert PC et al (2024) Health outcomes after myocardial infarction: A population study of 56 million people in England. PLoS Med 21(2):e1004343","journal-title":"PLoS Med"},{"issue":"14","key":"767_CR2","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.jacc.2016.01.069","volume":"67","author":"GW Stone","year":"2016","unstructured":"Stone GW, Selker HP, Thiele H, Patel MR, Udelson JE, Ohman EM et al (2016) Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. J Am Coll Cardiol 67(14):1674\u20131683","journal-title":"J Am Coll Cardiol"},{"issue":"27","key":"767_CR3","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1093\/eurheartj\/ehac223","volume":"43","author":"S Frantz","year":"2022","unstructured":"Frantz S, Hundertmark MJ, Schulz-Menger J, Bengel FM, Bauersachs J (2022) Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. Eur Heart J 43(27):2549\u20132561","journal-title":"Eur Heart J"},{"issue":"4","key":"767_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jacbts.2016.03.011","volume":"1","author":"JP Giblett","year":"2016","unstructured":"Giblett JP, Clarke SJ, Dutka DP, Hoole SP (2016) Glucagon-Like Peptide-1: A Promising Agent for Cardioprotection During Myocardial Ischemia. JACC Basic Transl Sci 1(4):267\u2013276","journal-title":"JACC Basic Transl Sci"},{"key":"767_CR5","doi-asserted-by":"crossref","unstructured":"Wong CK, Drucker DJ (2025) Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits. J Clin Invest. ;135(21)","DOI":"10.1172\/JCI194751"},{"issue":"12","key":"767_CR6","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","volume":"33","author":"J L\u00f8nborg","year":"2012","unstructured":"L\u00f8nborg J, Vejlstrup N, Kelb\u00e6k H, B\u00f8tker HE, Kim WY, Mathiasen AB et al (2012) Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 33(12):1491\u20131499","journal-title":"Eur Heart J"},{"issue":"1","key":"767_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ijcard.2012.09.204","volume":"167","author":"FJ Bernink","year":"2013","unstructured":"Bernink FJ, Timmers L, Diamant M, Scholte M, Beek AM, Kamp O et al (2013) Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: the EXAMI study. Int J Cardiol 167(1):289\u2013290","journal-title":"Int J Cardiol"},{"key":"767_CR8","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ijcard.2016.06.283","volume":"220","author":"ST Roos","year":"2016","unstructured":"Roos ST, Timmers L, Biesbroek PS, Nijveldt R, Kamp O, van Rossum AC et al (2016) No benefit of additional treatment with exenatide in patients with an acute myocardial infarction. Int J Cardiol 220:809\u2013814","journal-title":"Int J Cardiol"},{"issue":"5","key":"767_CR9","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ahj.2015.07.014","volume":"170","author":"WR Chen","year":"2015","unstructured":"Chen WR, Hu SY, Chen YD, Zhang Y, Qian G, Wang J et al (2015) Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 170(5):845\u2013854","journal-title":"Am Heart J"},{"issue":"9","key":"767_CR10","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1161\/ATVBAHA.113.301586","volume":"33","author":"JS Woo","year":"2013","unstructured":"Woo JS, Kim W, Ha SJ, Kim JB, Kim SJ, Kim WS et al (2013) Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol 33(9):2252\u20132260","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"767_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijcard.2015.12.009","volume":"208","author":"WR Chen","year":"2016","unstructured":"Chen WR, Tian F, Chen YD, Wang J, Yang JJ, Wang ZF et al (2016) Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction. Int J Cardiol 208:109\u2013114","journal-title":"Int J Cardiol"},{"key":"767_CR12","doi-asserted-by":"crossref","unstructured":"Chen WR, Chen YD, Tian F, Yang N, Cheng LQ, Hu SY et al (2016) Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment-Elevation Myocardial Infarction. Circ Cardiovasc Imaging. ;9(12)","DOI":"10.1161\/CIRCIMAGING.116.005146"},{"issue":"3","key":"767_CR13","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s12020-015-0798-0","volume":"52","author":"WR Chen","year":"2016","unstructured":"Chen WR, Shen XQ, Zhang Y, Chen YD, Hu SY, Qian G et al (2016) Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine 52(3):516\u2013526","journal-title":"Endocrine"},{"issue":"1","key":"767_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00395-021-00842-2","volume":"116","author":"B Del Garc\u00eda","year":"2021","unstructured":"Del Garc\u00eda B, Otaegui I, Rodr\u00edguez-Palomares JF, Bay\u00e9s-Genis A, Fern\u00e1ndez-Nofrer\u00edas E, Del Vilalta V et al (2021) Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI). Basic Res Cardiol 116(1):4","journal-title":"Basic Res Cardiol"},{"issue":"8","key":"767_CR15","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00380-015-0734-5","volume":"31","author":"T Nozue","year":"2016","unstructured":"Nozue T, Yamada M, Tsunoda T, Katoh H, Ito S, Iwaki T et al (2016) Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Heart Vessels 31(8):1239\u20131246","journal-title":"Heart Vessels"},{"issue":"1","key":"767_CR16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2337\/diabetes.54.1.146","volume":"54","author":"AK Bose","year":"2005","unstructured":"Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM (2005) Glucagon-like peptide 1 can directly protect the heart against ischemia\/reperfusion injury. Diabetes 54(1):146\u2013151","journal-title":"Diabetes"},{"key":"767_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1479-5876-11-84","volume":"11","author":"P Wohlfart","year":"2013","unstructured":"Wohlfart P, Linz W, H\u00fcbschle T, Linz D, Huber J, Hess S et al (2013) Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies. J Transl Med 11:84","journal-title":"J Transl Med"},{"issue":"3\u20134","key":"767_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12012-023-09789-3","volume":"23","author":"G Zhou","year":"2023","unstructured":"Zhou G, Wu H, Yang J, Ye M, Liu D, Li Y et al (2023) Liraglutide Attenuates Myocardial Ischemia\/Reperfusion Injury Through the Inhibition of Necroptosis by Activating GLP-1R\/PI3K\/Akt Pathway. Cardiovasc Toxicol 23(3\u20134):161\u2013175","journal-title":"Cardiovasc Toxicol"},{"issue":"1","key":"767_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s40471-025-00375-5","volume":"12","author":"LA Soares","year":"2025","unstructured":"Soares LA, Paniagua C, Nguyen J, Kojic A, Sanfrey ER, Reyome ME et al (2025) The Role of Glucagon-Like Peptide-1 Receptor Agonists in Post ST-Segment Elevation Myocardial Infarction Care: A Scoping Review. Curr Epidemiol Rep 12(1):22","journal-title":"Curr Epidemiol Rep"},{"issue":"7","key":"767_CR20","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1080\/07853890.2017.1306653","volume":"49","author":"M Huang","year":"2017","unstructured":"Huang M, Wei R, Wang Y, Su T, Li Q, Yang X et al (2017) Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials. Ann Med 49(7):552\u2013561","journal-title":"Ann Med"},{"issue":"2","key":"767_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10557-022-07360-w","volume":"38","author":"SY Wong","year":"2024","unstructured":"Wong SY, Lee A, Sia AHJ, Wo YJ, Teo YH, Teo YN et al (2024) Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials. Cardiovasc Drugs Ther 38(2):371\u2013389","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"767_CR22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00059-018-4748-5","volume":"45","author":"X Yang","year":"2020","unstructured":"Yang X, Liang Z (2020) Efficacy of liraglutide intervention in myocardial infarction: A meta-analysis of randomized controlled trials. Herz 45(5):461\u2013467","journal-title":"Herz"},{"key":"767_CR23","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"767_CR24","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"767_CR25","doi-asserted-by":"crossref","unstructured":"McGuinness LA, Higgins JPT (2020) Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synthesis Methods. ;1\u20137","DOI":"10.1002\/jrsm.1411"},{"key":"767_CR26","unstructured":"Wells GASB, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses: The Ottawa Hospital Research Institute; [cited 2026 April 30, at 15:01]. Available from: https:\/\/ohri.ca\/en\/who-we-are\/core-facilities-and-platforms\/ottawa-methods-centre\/newcastle-ottawa-scale"},{"issue":"7414","key":"767_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560","journal-title":"BMJ"},{"issue":"6","key":"767_CR28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00210-019-01625-2","volume":"392","author":"G Guan","year":"2019","unstructured":"Guan G, Zhang J, Liu S, Huang W, Gong Y, Gu X (2019) Glucagon-like peptide-1 attenuates endoplasmic reticulum stress-induced apoptosis in H9c2 cardiomyocytes during hypoxia\/reoxygenation through the GLP-1R\/PI3K\/Akt pathways. Naunyn Schmiedebergs Arch Pharmacol 392(6):715\u2013722","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"6","key":"767_CR29","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jacc.2008.10.033","volume":"53","author":"L Timmers","year":"2009","unstructured":"Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P et al (2009) Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53(6):501\u2013510","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"767_CR30","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1042\/CS20160061","volume":"130","author":"X Wang","year":"2016","unstructured":"Wang X, Ding Z, Yang F, Dai Y, Chen P, Theus S et al (2016) Modulation of myocardial injury and collagen deposition following ischaemia-reperfusion by linagliptin and liraglutide, and both together. Clin Sci (Lond) 130(15):1353\u20131362","journal-title":"Clin Sci (Lond)"},{"issue":"5","key":"767_CR31","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jacep.2017.12.015","volume":"4","author":"DS Chew","year":"2018","unstructured":"Chew DS, Heikki H, Schmidt G, Kavanagh KM, Dommasch M, Bloch Thomsen PE et al (2018) Change in Left Ventricular Ejection Fraction Following First Myocardial Infarction and Outcome. JACC Clin Electrophysiol 4(5):672\u2013682","journal-title":"JACC Clin Electrophysiol"},{"issue":"6","key":"767_CR32","doi-asserted-by":"publisher","first-page":"e0130894","DOI":"10.1371\/journal.pone.0130894","volume":"10","author":"K Aravindhan","year":"2015","unstructured":"Aravindhan K, Bao W, Harpel MR, Willette RN, Lepore JJ, Jucker BM (2015) Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart. PLoS ONE 10(6):e0130894","journal-title":"PLoS ONE"},{"issue":"5","key":"767_CR33","doi-asserted-by":"publisher","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","volume":"326","author":"B Park","year":"2024","unstructured":"Park B, Bakbak E, Teoh H, Krishnaraj A, Dennis F, Quan A et al (2024) GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage. Am J Physiol Heart Circ Physiol 326(5):H1159\u2013h76","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"767_CR34","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1124\/jpet.104.073890","volume":"312","author":"LA Nikolaidis","year":"2005","unstructured":"Nikolaidis LA, Doverspike A, Hentosz T, Zourelias L, Shen YT, Elahi D et al (2005) Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther 312(1):303\u2013308","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"767_CR35","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s10741-025-10523-0","volume":"30","author":"HF Siddiqui","year":"2025","unstructured":"Siddiqui HF, Waqas SA, Batool RM, Salim H, Minhas AMK, Hasni SF et al (2025) The effect of GLP-1 receptor agonists on cardiac remodeling in heart failure patients with preserved and reduced ejection fraction: a systematic review and meta-analysis. Heart Fail Rev 30(5):991\u20131004","journal-title":"Heart Fail Rev"},{"issue":"1","key":"767_CR36","first-page":"4554996","volume":"2022","author":"R Song","year":"2022","unstructured":"Song R, Qian H, Wang Y, Li Q, Li D, Chen J et al (2022) Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists. J Diabetes Res 2022(1):4554996","journal-title":"J Diabetes Res"},{"key":"767_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2023.01.049","volume":"647","author":"Q Zhu","year":"2023","unstructured":"Zhu Q, Luo Y, Wen Y, Wang D, Li J, Fan Z (2023) Semaglutide inhibits ischemia\/reperfusion-induced cardiomyocyte apoptosis through activating PKG\/PKC\u03b5\/ERK1\/2 pathway. Biochem Biophys Res Commun 647:1\u20138","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"767_CR38","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s10554-011-9975-2","volume":"28","author":"J Xu","year":"2012","unstructured":"Xu J, Song YB, Hahn JY, Chang SA, Lee SC, Choe YH et al (2012) Comparison of magnetic resonance imaging findings in non-ST-segment elevation versus ST-segment elevation myocardial infarction patients undergoing early invasive intervention. Int J Cardiovasc Imaging 28(6):1487\u20131497","journal-title":"Int J Cardiovasc Imaging"},{"issue":"22","key":"767_CR39","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1016\/j.jacc.2024.02.056","volume":"83","author":"GP Welt Frederick","year":"2024","unstructured":"Welt Frederick GP, Batchelor W, Spears JR, Penna C, Pagliaro P, Ibanez B et al (2024) Reperfusion Injury in Patients With Acute Myocardial Infarction. JACC 83(22):2196\u20132213","journal-title":"JACC"},{"issue":"15","key":"767_CR40","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.jacc.2025.07.064","volume":"86","author":"A Imbesi","year":"2025","unstructured":"Imbesi A, Greco A, Spagnolo M, Laudani C, Raffo C, Finocchiaro S et al (2025) Targeting Inflammation After Acute Myocardial Infarction. J Am Coll Cardiol 86(15):1146\u20131169","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"767_CR41","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.jacc.2025.08.027","volume":"86","author":"M Galli","year":"2025","unstructured":"Galli M, Benenati S, Laudani C, Simeone B, Sarto G, Ortega-Paz L et al (2025) Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. J Am Coll Cardiol 86(20):1805\u20131819","journal-title":"J Am Coll Cardiol"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-026-00767-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-026-00767-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-026-00767-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:21:20Z","timestamp":1784618480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43044-026-00767-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["767"],"URL":"https:\/\/doi.org\/10.1186\/s43044-026-00767-y","relation":{},"ISSN":["2090-911X"],"issn-type":[{"value":"2090-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"These meta-analyses are only based on data from previously published studies. No additional ethical approval or consent was obtained for this study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"55"}}